Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α

Samankaltaisia teoksia

• Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
  Tekijä: Van den Bosch, F., et al.
  Julkaistu: (2000)
• Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
  Tekijä: Kruithof, E, et al.
  Julkaistu: (2002)
• Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
  Tekijä: Kruithof, E, et al.
  Julkaistu: (2005)
• Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis
  Tekijä: Kruithof, E, et al.
  Julkaistu: (2002)
• Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
  Tekijä: Baeten, D, et al.
  Julkaistu: (2001)